John de Groot

19.4k total citations · 5 hit papers
219 papers, 9.7k citations indexed

About

John de Groot is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, John de Groot has authored 219 papers receiving a total of 9.7k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Genetics, 55 papers in Pulmonary and Respiratory Medicine and 55 papers in Oncology. Recurrent topics in John de Groot's work include Glioma Diagnosis and Treatment (157 papers), Brain Metastases and Treatment (37 papers) and Cancer Genomics and Diagnostics (26 papers). John de Groot is often cited by papers focused on Glioma Diagnosis and Treatment (157 papers), Brain Metastases and Treatment (37 papers) and Cancer Genomics and Diagnostics (26 papers). John de Groot collaborates with scholars based in United States, Netherlands and Canada. John de Groot's co-authors include Yuji Piao, Gregory N. Fuller, Harald Sontheimer, Monica Loghin, Amy B. Heimberger, Sudhakar Tummala, Mark R. Gilbert, Partow Kebriaei, Jason R. Westin and Sherry Adkins and has published in prestigious journals such as Physical Review Letters, Nature Medicine and Nature Communications.

In The Last Decade

John de Groot

207 papers receiving 9.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

2017 1.6k citations John de Groot et al. profile →
Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study

2015 433 citations John de Groot, Patrick Y. Wen et al. Neuro-Oncology profile →
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

2017 308 citations Martina Ott, John de Groot et al. Neuro-Oncology profile →
Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial

2024 54 citations John de Groot et al. profile →
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma

2024 52 citations Kazim Narsinh, Jacob S. Young et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John de Groot United States	52	3.8k	3.2k	3.0k	2.0k	1.8k	219	9.7k
Ian F. Parney United States	49	4.3k 1.1×	2.6k 0.8×	2.1k 0.7×	1.2k 0.6×	1.9k 1.1×	198	9.3k
Matija Snuderl United States	40	2.6k 0.7×	2.2k 0.7×	3.2k 1.1×	2.2k 1.1×	684 0.4×	188	9.2k
Manish K. Aghi United States	59	4.1k 1.1×	2.3k 0.7×	3.5k 1.2×	1.7k 0.9×	1.3k 0.8×	317	12.1k
Manmeet S. Ahluwalia United States	49	4.6k 1.2×	3.8k 1.2×	1.9k 0.6×	1.2k 0.6×	1.4k 0.8×	398	9.6k
Daniel P. Cahill United States	44	4.2k 1.1×	2.5k 0.8×	4.3k 1.4×	2.5k 1.3×	654 0.4×	176	9.7k
Donald M. O’Rourke United States	53	3.4k 0.9×	2.0k 0.6×	3.4k 1.1×	1.8k 0.9×	1.3k 0.7×	210	8.9k
Nicholas Butowski United States	41	3.5k 0.9×	1.4k 0.4×	2.0k 0.7×	1.1k 0.6×	1.1k 0.6×	188	6.3k
Peter Hau Germany	43	6.9k 1.8×	2.8k 0.9×	5.1k 1.7×	3.2k 1.7×	846 0.5×	189	11.9k
Chetan Bettegowda United States	43	1.9k 0.5×	1.7k 0.5×	2.3k 0.7×	1.5k 0.8×	795 0.5×	306	8.7k
Kristin Waite United States	38	4.1k 1.1×	1.4k 0.4×	3.9k 1.3×	1.7k 0.8×	1.0k 0.6×	103	10.0k

Countries citing papers authored by John de Groot

Since Specialization

Citations

This map shows the geographic impact of John de Groot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John de Groot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John de Groot more than expected).

Fields of papers citing papers by John de Groot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John de Groot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John de Groot. The network helps show where John de Groot may publish in the future.

Co-authorship network of co-authors of John de Groot

This figure shows the co-authorship network connecting the top 25 collaborators of John de Groot. A scholar is included among the top collaborators of John de Groot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John de Groot. John de Groot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Young, Jacob S., Alexa Semonche, Ramin A. Morshed, et al.. (2025). Focused ultrasound therapy as a strategy for improving glioma treatment. Journal of neurosurgery. 142(6). 1635–1644. 4 indexed citations

Gallus, Marco, et al.. (2024). Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations. Neuro-Oncology. 27(2). 352–368. 3 indexed citations

Schumacher, Karl Maria, Soetkin Vlassak, Todd A. Swanson, et al.. (2024). Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion. The Oncologist. 30(1). 1 indexed citations

Khan, Sabbir, Emmanuel Martínez-Ledesma, Jian‐Wen Dong, et al.. (2023). Neuronal differentiation drives the antitumor activity of mitogen-activated protein kinase kinase (MEK) inhibition in glioblastoma. Neuro-Oncology Advances. 5(1). vdad132–vdad132. 3 indexed citations

Majd, Nazanin, Yang Liu, Kristin Alfaro-Munoz, et al.. (2023). TMIC-58. ALTERATIONS IN GLIOBLASTOMA TUMOR MICROENVIRONMENT TRANSCRIPTOME AFTER TREATMENT WITH PEMBROLIZUMAB. Neuro-Oncology. 25(Supplement_5). v291–v291. 1 indexed citations

Lin, Kevin, Laine Goudy, Joshua J. Pak, et al.. (2023). CRISPR-Based Epigenome Editing and Genome Wide Screening Define Mediators of Chemotherapy Response in Glioblastoma. International Journal of Radiation Oncology*Biology*Physics. 117(2). S42–S43. 2 indexed citations

Ellingson, Benjamin M., Patrick Y. Wen, Susan M. Chang, et al.. (2023). Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology. 25(6). 1017–1028. 25 indexed citations

Groot, Patricia M. de, Octavio Arevalo, Komal Shah, et al.. (2022). Imaging Primer on Chimeric Antigen Receptor T-Cell Therapy for Radiologists. Radiographics. 42(1). 176–194. 12 indexed citations

Soffietti, Riccardo, Chetan Bettegowda, Ingo K. Mellinghoff, et al.. (2022). Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology. 24(6). 855–871. 63 indexed citations

10.

Majd, Nazanin, Timothy A. Yap, W. K. Alfred Yung, & John de Groot. (2020). The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. SHILAP Revista de lepidopterología. 3(4). 157–164. 3 indexed citations

11.

Zheng, Siyuan, Kristin Alfaro-Munoz, Wei Wei, et al.. (2019). Prospective Clinical Sequencing of Adult Glioma. Molecular Cancer Therapeutics. 18(5). 991–1000. 15 indexed citations

12.

Wu, Shaofang, Feng Gao, Siyuan Zheng, et al.. (2019). EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma. Clinical Cancer Research. 26(6). 1395–1407. 34 indexed citations

13.

Goswami, Sangeeta, Thomas Walle, Andrew Cornish, et al.. (2019). Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nature Medicine. 26(1). 39–46. 251 indexed citations

14.

Rogers, Leland, Minhee Won, Michael A. Vogelbaum, et al.. (2019). High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539. International Journal of Radiation Oncology*Biology*Physics. 106(4). 790–799. 114 indexed citations

15.

Zinn, Pascal O., Sanjay K. Singh, Aikaterini Kotrotsou, et al.. (2018). A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models. Clinical Cancer Research. 24(24). 6288–6299. 80 indexed citations

16.

Park, Soon Young, Yuji Piao, Kang Jin Jeong, Jian‐Wen Dong, & John de Groot. (2016). Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models. Molecular Cancer Therapeutics. 15(9). 2187–2197. 68 indexed citations

17.

Groot, John de, Kathleen R. Lamborn, Susan M. Chang, et al.. (2011). Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. Journal of Clinical Oncology. 29(19). 2689–2695. 168 indexed citations

18.

Groot, John de, Yuji Piao, Hai T. Tran, et al.. (2011). Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research. 17(14). 4872–4881. 51 indexed citations

19.

Milano, Vanessa, Yuji Piao, Tiffany A. LaFortune, & John de Groot. (2009). Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Molecular Cancer Therapeutics. 8(2). 394–406. 102 indexed citations

20.

Benjamin, Ramsis, Fred H. Hochberg, Elizabeth Fox, et al.. (2004). Review of microdialysis in brain tumors, from concept to application:First Annual Carolyn Frye-Halloran Symposium. Neuro-Oncology. 6(1). 65–74. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact